TET2 and acute myeloid leukemia: However, in the intermediate group, the median number of genetic events was one (range 0–3), although remarkably, no risk-defining abnormalities were found in 14 patients (37.8%); other recurrent AML mutations not included in the ELN2022 stratification (IDH1/2, TET2, DNMT3A or No-bZIP CEBPA) were present in 78% of these patients (n = 11/14).